进行比较18 F-PSMA-1007 PET/CT、18 F-FDG PET/CT和68Ga-PSMA PET/CT在前列腺癌诊断价值方面的研究。使用PubMed、Cochrane Library、Embase、CNKI、VIP、万方等中外数据库，系统检索从建库到2022年6月1日的相关临床研究。研究与18 F-PSMA-1007 PET/CT、18 F-FDG PET/CT、68Ga-PSMA PET/CT等方法诊断前列腺癌有关的临床研究。两名调查人员独立筛选文献、提取数据，并使用QUADAS-2评估纳入研究中的数据的偏倚风险。使用Review Manager 5.4、Stata 14.0和Meta-disc 1.4软件进行荟萃分析，比较不同方法在前列腺癌诊断方面的效果。本研究共纳入27项研究，包括2891名研究对象。荟萃分析结果显示，18 F-PSMA-1007 PET/CT、18 F-FDG PET/CT和68Ga-PSMA PET/CT的合并敏感性分别为0.912（95% CI：0.883-0.936）、0.748（95% CI：0.698-0.795）和0.916（95% CI：0.896-0.934）；合并特异性分别为0.878（95% CI：0.844-0.907）、0.639（95% CI：0.589-0.687）和0.734（95% CI：0.685-0.779）；阳性似然比分别为6.335（95% CI：4.288-9.357）、2.282（95% CI：1.497-3.477）和3.593（95% CI：2.986-4.323）；阴性似然比分别为0.878（95% CI：0.844-0.907）、0.374（95% CI：0.280-0.499）和0.110（95% CI：0.083-0.144）；诊断比值比分别为65.125（95% CI：34.059-124.53）、7.094（95% CI：4.091-12.301）和29.722（95% CI：20.141-43.863）；阳性后验概率分别为64%、38%和62%；曲线下面积分别为0.95（95% CI：0.93-0.97）、0.81（95% CI：0.78-0.84）和0.96（95% CI：0.92-0.98）。漏斗图显示纳入的文献中没有明显的出版偏倚。当前证据表明，相较于18 F-FDG PET/CT，18 F-PSMA-1007 PET/CT和68Ga-PSMA PET/CT具有更高的前列腺癌诊断功效，其中68Ga-PSMA PET/CT在前列腺癌诊断敏感性方面稍高，而18 F-PSMA-1007 PET/CT在特异性和确诊阳性率方面可能更高。由于纳入样本和文献质量的限制，上述结论需要通过扩大样本量和提高质量来进一步验证。© 2023. 国际癌症影像学会（ICIS）。

To compare 18 F-PSMA-1007 PET/CT, 18 F-FDG PET/CT and 68Ga-PSMA PET/CT in the diagnostic value of prostate cancer.The Chinese and foreign databases, such as Pubmed, Cochrane Library, Embase, CNKI, VIP, Wanfang, etc., were systematically searched within the period from the establishment of the database to June 1, 2022. Clinical studies related to the diagnosis of prostate cancer by methods such as 18 F-PSMA-1007 PET/CT, 18 F-FDG PET/CTCT, 68Ga-PSMA PET/CT, were researched. Two (2) investigators independently screened literatures, extracted data, and assessed the risk of bias when these data were included in the studies with the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2). Review Manager5.4, Stata 14.0, and Meta-disc 1.4 software were used for meta-analysis to compare the efficacy of different methods in the diagnose of prostate cancer.Twenty-seven (27) studies, including 2891 subjects were included in our study. Meta-analysis results showed that the pooled sensitivities of 18 F-PSMA-1007 PET/CT, 18 F-FDG PET/CT, and 68Ga-PSMA PET/CT were 0.912 (95%CI: 0.883-0.936), 0.748 (95%CI: 0.698-0.795), and 0.916 (95%CI: 0.896-0.934), respectively; the pooled specification were 0.878 (0.844-0.907), 0.639 (95%CI: 0.589-0.687), and 0.734 (95%CI: 0.685-0.779), respectively; the positive likelihood ratios were 6.335 (95%CI: 4.288-9.357), 2.282 (95%CI: 1.497-3.477), and 3.593 (95%CI: 2.986-4.323), respectively; the negative likelihood ratios were 0.878 (95%CI: 0.844-0.907), 0.374 (95%CI: 0.280-0.499), and 0.110 (95%CI: 0.083-0.144), respectively; the diagnostic odds ratios were 65.125 (95%CI: 34.059-124.53), 7.094 (95%CI: 4.091-12.301), and 29.722 (95%CI: 20.141-43.863), respectively; the positive posterior probability was 64%, 38%, and 62%, respectively; the area under the SPOC curve was 0.95 (95%CI: 0.93-0.97), 0.81 (95%CI: 0.78-0.84), and 0.96 (95%CI: 0.92-0.98), respectively. The funnel plots indicated that there was no significant publication bias in the included literatures.The current evidences showed that 18 F-PSMA-1007 PET/CT and 68Ga-PSMA PET/CT had higher diagnostic efficacy of prostate cancer compared with 18 F-FDG PET/CT, among which 68Ga-PSMA PET/CT was slightly higher in the sensitivity of the diagnosis of prostate cancer, while 18 F-PSMA-1007 PET/CT may have higher efficacy in specificity and confirmed positive rate. Due to the limitations of the quality of the included samples and literatures, the above conclusions should be further validated by expanding the sample size and improving the quality.© 2023. International Cancer Imaging Society (ICIS).